Russ Conroy is an Assistant Editor for CancerNetwork. He grew up in Hillsborough, New Jersey, and graduated from Rutgers University-New Brunswick in 2022.
On the weekends, he likes to unwind by playing video games with friends, tailgating at Rutgers football games with his family, or building his music collection with a visit to Princeton Record Exchange.
Durvalumab Plus Tremelimumab Fails to Meet Survival End Point in Phase 3 Metastatic NSCLC StudyJanuary 3rd 2023
The phase 3 NEPTUNE study indicated that durvalumab plus tremelimumab did not reach an amended primary end point of improved overall survival among patients with metastatic non–small cell lung cancer with a blood tumor mutational burden of at least 20 mut/Mb, though the combination did yield a numerical reduction in risk of death.
Niraparib Maintenance Demonstrates Favorable OS Trend in Platinum-Sensitive Recurrent Ovarian CancerDecember 29th 2022
Findings from the phase 3 NORA study identified a numerically longer median overall survival among patients with platinum-sensitive recurrent ovarian cancer treated with maintenance niraparib regardless of BRCA mutation status.
Durvalumab Yields Clinically Meaningful OS Benefit but Misses the Mark in PD-L1–High Metastatic NSCLCDecember 28th 2022
Data from the phase 3 PEARL trial indicated that durvalumab yielded a clinically significant improvement in overall survival but did not meet statistical significance among patients with stage IV non–small cell lung cancer with high PD-L1 expression.
FDA Grants Breakthrough Therapy Designation to Adagrasib/Cetuximab for KRAS G12C+ CRCDecember 22nd 2022
The FDA granted breakthrough therapy designation to adagrasib plus cetuximab for patients with KRAS G12C–mutated advanced colorectal cancer based on findings from the phase 1b cohort of the KRYSTAL-1 trial.
FDA Approves FoundationOne Liquid CDx Assay for Identifying EGFR+ NSCLC Eligible for TKI InhibitorsDecember 21st 2022
The FDA has approved the FoundationOne Liquid CDx as a companion diagnostic for identifying patients with non-small cell lung cancer harboring EGFR mutations who may benefit from treatment with specific tyrosine kinase inhibitors.
FDA Accepts sBLAs for Enfortumab Vedotin/Pembrolizumab in Advanced or Metastatic Urothelial CancerDecember 21st 2022
The FDA has set the Prescription Drug User Fee Act date for April 21, 2023 for each supplemental biologics license application of enfortumab vedotin-ejfv and pembrolizumab in urothelial carcinoma.
FDA Approves Additional Indication for Pemetrexed Injection Plus Pembrolizumab/Chemo in Metastatic NSCLCDecember 19th 2022
The FDA has approved an additional indication for pemetrexed injection plus pembrolizumab and chemotherapy in the treatment of metastatic non–small cell lung cancer without EGFR or ALK tumor aberrations.
Cabozantinib/Atezolizumab Fails to Reach Survival End Point But Is Safe in Metastatic NSCLCDecember 16th 2022
Findings from the phase 3 CONTACT-01 trial indicated that cabozantinib and atezolizumab did not reach the primary end point of overall survival in patients with metastatic non–small cell lung cancer.
Teclistamab Combination Therapy Produces Promising Safety Profile in Relapsed/Refractory Multiple MyelomaDecember 10th 2022
Findings from the phase 1b MajesTEC-2 trial indicated that teclistamab in combination with daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma.
FDA Grants BTD to Revumenib for Relapsed/Refractory KMT2Ar Acute LeukemiaDecember 6th 2022
Revumenib, which was given a breakthrough therapy designation by the FDA, may be beneficial in the management of relapsed or refractory KMT2A-rearranged acute leukemia based on data from the phase 1 AUGMENT-101 trial.
Dostarlimab/Chemotherapy Combo Elicits Significant Survival Benefit in Advanced/Recurrent Endometrial CancerDecember 6th 2022
Treatment with dostarlimab plus chemotherapy demonstrated a statistically significant improvement in progression-free survival compared with placebo and chemotherapy among patients with advanced or recurrent endometrial cancer.
Adjuvant Pembrolizumab Improves Quality-of-Life Vs Interferon α or Ipilimumab in Resected MelanomaDecember 5th 2022
A secondary analysis from the phase 3 SWOG S1404 trial indicated that adjuvant pembrolizumab yielded improved patient-reported outcomes compared with high-dose interferon α or ipilimumab in the treatment of patients with high-risk resected melanoma.
FDA Accepts BLA for Denileukin Diftitox in Cutaneous Persistent/Recurrent T-Cell LymphomaDecember 4th 2022
The FDA’s acceptance of the biologics license application for denileukin diftitox for the treatment of patients with cutaneous persistent or recurrent T-cell lymphoma was supported by data from a pivotal phase 3 trial.
FDA Grants Fast Track Designation to Batiraxcept for Kidney Cancer SubsetNovember 30th 2022
The FDA’s decision to grant fast track designation to batiraxcept for treating patients with advanced or metastatic clear cell renal cell carcinoma — a type of kidney cancer — was supported by data from a phase 1b trial.
Daratumumab Combination Demonstrates Efficacy in Relapsed/Refractory Myeloma With EMDNovember 30th 2022
Among patients with extramedullary multiple myeloma, a regimen consisting of daratumumab plus dexamethasone, cyclophosphamide, etoposide, and cisplatin yielded a complete remission rate of 35.5% and an overall response rate of 67.7%.
Addition of Rezvilutamide to ADT Improves OS and rPFS Vs Bicalutamide/ADT in Hormone-Sensitive Prostate CancerNovember 30th 2022
Rezvilutamide with androgen-deprivation therapy yielded improved overall survival and radiographic progression-free survival compared with bicalutamide and androgen-deprivation therapy in patients with high-volume metastatic hormone-sensitive prostate cancer.
Real-World Findings Suggest mFOLFOX6 Treatment Resulted in Less Oxaliplatin Vs Historic Control in Colon CancerNovember 29th 2022
Real-world patients with stage III colon cancer who were treated in the community practice setting with modified FOLFOX6 received less oxaliplatin vs historic controls from the phase 3 MOSAIC trial.
Data Support Whole Brain Irradiation Reduction in Pediatric Cancer SurvivorsNovember 28th 2022
Results from a pooled case control study indicate that meninges are very radiosensitive in pediatric patients who were treated at prior to age 10 years, supporting reduced dose whole brain irradiation in this population.
Cilta-cel Produces Early Long-Lasting Responses in Pretreated Relapsed/Refractory Multiple MyelomaNovember 28th 2022
Data from the phase 2 CARTIFAN-1 study highlighted a favorable risk-benefit profile for a single infusion of ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma.